Company

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

Fineline Cube
By
Fineline Cube
3 Min Read
Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
Summarize with AI

Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to RMB 7.7 billion (USD 1.1 billion). Innovative drug business surged 27.9% to RMB 6.304 billion (USD 913 million), driving profits attributable to shareholders up 86.2% to RMB 1.344 billion (USD 194 million). The company launched two new innovative products – Quviviq (daridorexan) for insomnia and Enzeshu (suvemcitug) for platinum-resistant ovarian cancer – expanding its neuroscience and oncology franchises.

Contents
- Advertisement -

Financial Highlights

Metric2025 ResultYoY ChangeStrategic Driver
Total RevenueRMB 7.7B (USD 1.1B)+16.5%Innovative drug momentum + new product launches
Innovative Drug RevenueRMB 6.304B (USD 913M)+27.9%81.9% of total revenue – transformation complete
Profit AttributableRMB 1.344B (USD 194M)+86.2%Operating leverage + high-margin innovation mix
NeuroscienceRMB 2.753B (USD 398M)+26.6%Core franchise strength
AutoimmuneRMB 1.892B (USD 274M)+4.5%Stable contribution
OncologyRMB 1.987B (USD 287M)+53.0%Fastest-growing segment – Enzeshu launch impact
OtherRMB 1.099B (USD 159M)-18.7%Portfolio rationalization

2025 New Product Launches

ProductIndicationDifferentiationLaunch Impact
Quviviq (daridorexan)Adult insomnia (sleep onset/maintenance)Non-controlled substance (Schedule IV exempt) – addresses abuse liability concerns vs. zolpidemNeuroscience expansion – RMB 500M+ peak potential
Enzeshu (suvemcitug)Platinum-resistant ovarian/fallopian tube/peritoneal cancerCombination with paclitaxel, doxorubicin liposomes, or topotecan; ≤1 prior systemic therapy positioningOncology 53% growth driver; addresses high unmet need in recurrent disease

Strategic Context: Therapeutic Area Performance

SegmentRevenueGrowthKey AssetsStrategic Priority
NeuroscienceRMB 2.753B+26.6%Mustard (edible bird’s nest extract), Quviviq launchCore franchise – largest revenue base; insomnia addition
OncologyRMB 1.987B+53.0%Enzeshu launch, Endostar (rh-endostatin)High-growth engine – targeted therapies + immuno-oncology
AutoimmuneRMB 1.892B+4.5%Xinmei (triptolide), Iremod (iguratimod)Stable cash flow – established RA/lupus positioning
OtherRMB 1.099B-18.7%Legacy productsPortfolio optimization – divestment of non-core assets

Forward‑Looking Statements
This brief contains forward‑looking statements regarding 2026 revenue growth, Quviviq/Enzeshu market penetration, and therapeutic area expansion. Actual results may differ due to competitive dynamics in insomnia (lemborexant, daridorexan) and ovarian cancer (PARP inhibitors, bevacizumab), and NRDL negotiation outcomes for new products.-Fineline Info & Tech

2026032502204_cDownload
TAGGED:
Share This Article
Previous Article GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China's Adult Self-Paid Market GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
Next Article China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

You May also Like

CompanyDrug

AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study

CompanyDrug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

CompanyDrug

Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals
CompanyDeals

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals

Show More